| Males | Females | ||||||
---|---|---|---|---|---|---|---|---|
Target concentration (mg/m3) | 0 | 0.05 | 0.25 | 5.0 | 0 | 0.05 | 0.25 | 5.0 |
Number examined | 10/10 | 10/8 | 10/9 | 10/10 | 10/8 | 9/10 | 10/10 | 10/10 |
(24Â h/90Â days) | ||||||||
Black particle deposition | Â | Â | Â | Â | Â | Â | Â | Â |
minimal | - | - | 8/5 | - | - | - | 5/3 | 1 |
slight | - | - | -/2 | 6/3 | - | - | - | 7/1 |
moderate | - | - | - | 4/7 | - | - | - | 1/9 |
Mean severitya | - | - | 0.8/0.9 | 2.4/2.7 | - | - | 0.5/0.3 | 1.8/2.9 |
Increased lymphocytes, cortex/paracortex | Â | Â | Â | Â | Â | Â | Â | Â |
minimal | - | - | 3/- | 4/7 | - | - | 1/- | 3/6 |
slight | - | - | - | 3/2 | - | - | - | 7/- |
moderate | - | - | - | 3/- | - | - | - | - |
Mean severitya | - | - | 0.3/- | 1.9/1.1 | - | - | 0.1/- | 1.7/0.6 |
Endothelial vacuolation, high endothelial venule | Â | Â | Â | Â | Â | Â | Â | Â |
minimal | - | - | 1/- | 1/2 | - | - | - | 2/5 |
slight | - | - | 1/- | 7/1 | - | - | - | 5/- |
Mean severitya | - | - | 0.3/- | 1.5/0.4 | - | - | - | 1.2/0.5 |